Histone deacetylase (HDAC) inhibition leads to dynamic changes in the epigenetic landscape that is postulated to alter the expression of critical mediators of cellular proliferation and death. While current HDAC inhibitors have shown to be efficacious in the treatment of specific hematologic malignancies, their therapeutic utility in epithelial-based cancers warrants further evaluation. Moreover, the mechanisms of HDAC inhibition-induced cancer cell death are not completely understood. Therefore, elucidation of the underlying pathways engaged by HDAC inhibition may enable the development of more effective therapeutic strategies. Here, we report that HDAC inhibition in human breast and lung carcinoma cells activates an apoptotic mechanism mediated by microRNA (miRNA) and induced by the oncogene MYC. Specifically, following HDAC inhibition, MYC, which normally represses miR-15 and let-7 families, transcriptionally activated their expression and MYC was required for this miRNA upregulation. As a result, transcript levels of the tumor-suppressive miR-15 and let-7 families increased, which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-X L , respectively. MYC was also required for the downregulation of BCL-2 and BCL-X L following HDAC inhibition. Blocking the binding sites of the miR-15 and let-7 families in the 3′-untranslated regions of BCL-2 and BCL-X L protected against HDAC inhibition-induced apoptosis. These results provide important insight into the molecular underpinnings of HDAC inhibition-induced cell death in breast and lung cancer and reveal a tumor-suppressive role for MYCregulated miRNA that is activated with HDAC inhibition.
Aberrant gene transcription is a defining feature of cancer, and alterations in transcription regulation often lead to cellular transformation. 1 Complex mechanisms regulate transcription, including the addition or removal of chemical modifications, such as acetyl groups, to histone tails. 2 Deregulation in the expression and/or activity of histone deacetylase (HDAC) enzymes, which remove acetyl groups, leads to alterations in gene expression and has been linked to the development of cancer. 2 The predominant biological outcome following exposure of cells to inhibitors of HDACs has been the selective death of malignant cells. 3 Although HDAC inhibitors have provided clinical benefit to the treatment of specific hematological malignancies, its impact on solid organ cancer treatment is less clear and the underlying mechanisms behind HDAC inhibition (HDACi)-induced tumor cell apoptosis remain unresolved.
Although the mechanism of action of HDAC inhibitors should favor chromatin decondensation and a global increase in gene transcription, only a small percentage of genes appears to be affected. 4 This suggests that post-transcriptional mechanisms of gene regulation are likely involved in the molecular events following HDACi. One such mechanism that has been linked to HDAC regulation includes microRNA (miRNA). [5] [6] [7] [8] miRNA comprise a class of noncoding RNA that post-transcriptionally regulate the expression of target mRNA, typically resulting in decreased translation. 9 The potential for miRNA-guided regulation of gene expression is significant, as it is predicted that the majority of all mRNAs are under miRNA control and that a single miRNA can target many mRNA. 9 Therefore, HDACiinduced changes in one or more miRNA are capable of eliciting a significant downstream biological response.
Cancers often present with reduced levels of mature miRNA as compared with normal tissue of the same origin. 10, 11 In B-cell lymphomas, downregulation of miRNA expression was reported to be the result of widespread transcriptional repression by the oncogenic transcription factor MYC. the miR-15 and let-7 families in breast and lung cancer, and that upon HDACi, these miRNA were transcriptionally activated by MYC. Blocking the ability of miR-15 and let-7 families from targeting BCL-2 and BCL-X L , respectively, resulted in carcinoma cell survival. Our data reveal a previously unknown mechanism of MYC-induced apoptosis mediated by miRNA that is activated in breast and lung cancer cells by HDACi.
Results
HDACi induces transcription of the miR-15 and let-7 families in breast and lung cancer cells. Cancer cells frequently select for downregulation of miRNA that inhibit growth and mediate apoptosis.
14 For example, the miR-15 and let-7 families, both of which have been shown to induce apoptosis and inhibit tumorigenesis, 15 are significantly downregulated in most human cancers, including breast and lung carcinoma. 10, 11, 13, 14 A recent mechanism of miRNA repression was reported to be mediated, in part, by the recruitment of HDACs to miRNA promoters. 5 As such, we sought to determine whether HDACs contributed to the transcriptional repression of the miR-15 and let-7 families in breast and lung cancers. Following HDACi with Depsipeptide (Depsi, panclass I HDAC inhibitor), an increase in levels of representative members of the miR-15 and let-7 families (miR-15a and let-7a, respectively) was observed in all four breast and lung cancer cell lines evaluated compared to vehicle control (dimethyl sulfoxide (DMSO)) ( Figure 1a) . Expression of other miRNA (e.g., miR-301) did not change upon HDACi, indicating that HDACi did not lead to the upregulation of all miRNA. Analogous results were obtained with suberoylanilide hydroxamic acid (SAHA, a pan-HDAC inhibitor) and RGFP966 (966, an HDAC3-selective inhibitor) (Supplementary Figure 1A) . The increase in expression of the miRNA was specific for transformed cells, as peripheral blood mononuclear cells (PBMCs) did not show an induction of miR-15a and let-7a following HDACi (Supplementary Figure 1B) .
We postulated that the increased miRNA levels we observed were likely due to increased transcription. To determine whether the miR-15 and let-7 families were actively being transcribed following HDACi, we first assessed the expression of the primary miRNA transcripts for miR-15a and let-7a, representative members of both families. Following HDACi, we detected an increase in levels of pri-miR-15a and pri-let-7a in the breast and lung cancer cell lines (Figure 1b) . Additionally, western blotting revealed an increase in global histone acetylation marks associated with active transcription following HDACi with Depsi, SAHA or 966 (Figure 1c and Supplementary Figure 1C) .
Global acetylation of histones is typically associated with open and active chromatin; therefore, we next evaluated the transcriptional status of the promoters of the miR-15 and let-7 families. We performed chromatin immunoprecipitation (ChIP) with the MDA-MB-231 breast cancer cell line following administration of HDACi or vehicle control. Specifically, we assessed the enrichment of a phosphorylated form of RNA polymerase II (serine 2 phosphorylated; RNAPII-p-Ser2), which is indicative of RNAPII engaged in transcriptional elongation. Notably, HDACi resulted in a significant enrichment of RNAPII-p-Ser2 at the promoter regions of the miR-15 family (miR-15a/16-1, miR-195/497) and the let-7a/f cluster ( Figure 1d ). RNAPII enrichment was not detected at regions upstream of the miRNA promoters or in cells that received DMSO vehicle control. Furthermore, H3K9K14ac (histone 3 with lysine 9 and 14 acetylation), an acetylation mark associated with transcriptionally active and open chromatin, was also enriched at the promoter regions of miR-15a/16-1, miR-195/497 and let-7a/f following HDACi (Figure 1e ). These results demonstrate that HDACi alleviates the repression of the miR-15 and let-7 families observed in malignant breast and lung cells, inducing their transcriptional upregulation.
MYC is required to mediate the HDACi-induced increase in the miR-15 family and let-7a. The oncogenic transcription factor MYC has been shown to transcriptionally activate or repress the expression of protein-coding genes and noncoding RNA, including miRNA. 16 Previously, reduced expression of the miR-15 and let-7 families in human B-cell lymphoma was reportedly due to MYC-mediated transcriptional repression at their promoter regions. 12 Therefore, we first investigated whether MYC was enriched at the promoter regions of the miR-15a/16-1, miR-195/497 and let-7a/f clusters in the presence and absence of HDACi using ChIP. MYC enrichment was detected in MDA-MB-231 cells that had received either DMSO vehicle control or the HDACi Depsi (Figure 2a ). However, no enrichment was detected at regions upstream of the miRNA promoters (Figure 2a ). In addition, ENCODE (encyclopedia of DNA elements) ChIP-seq data 17 from human breast and lung cell lines was evaluated and also showed that MYC was enriched at these same miRNA promoter regions (Figure 2b ). These results suggest that MYC is bound to the promoters of the miR-15 and let-7 families regardless of their transcriptional status and HDACi.
To determine whether MYC was necessary to transcriptionally activate the expression of the miR-15 and let-7 families following HDACi, MDA-MB-231 breast cancer cells were transfected with a vector encoding a MYC-specific short hairpin RNA (shRNA) or a non-targeting (NT) shRNA ( Figure 2c ). Upon knockdown of MYC, the HDACi-induced increase in miR-15a, miR-195 and let-7a levels were significantly blunted (Figure 2c ). These data demonstrate that MYC is required to mediate the increase in miR-15 and let-7 families induced by HDACi.
BCL-2 and BCL-X L expression is reduced by HDACi and requires MYC. Post-transcriptional mRNA regulation is mediated, in part, by miRNA. 9, 14 Given the significant increase in the levels of the miR-15 and let-7 families following HDACi, we questioned whether this would impact the expression of known targets of these two miRNA families. Specifically, we evaluated the expression of crucial prosurvival proteins BCL-2 and BCL-X L , as their 3′-UTRs are wellcharacterized targets of the miR-15 and let-7 families, respectively ( Figure 3a) . 14, 15 To test this, breast and lung cancer cell lines were administered Depsi or vehicle control (DMSO). Compared with cells exposed to vehicle control, HDACi resulted in significantly decreased BCL-2 and BCL-X L protein levels in all four carcinoma lines (Figure 3b ). Figure 2a) . Analysis of BCL-2 and BCL-X L mRNA in breast and lung cancer cells showed that both were significantly decreased upon HDACi, indicating that the decrease in protein expression was likely due to a reduction in BCL-2 and BCL-X L mRNA (Figure 3c ). The were transfected with a vector encoding a MYC shRNA or an NT shRNA and then treated with Depsi. Levels of both BCL-2 and BCL-X L proteins decreased within 12 h following HDACi in the cells that had received the NT shRNA (Figure 3d) . However, MYC knockdown greatly inhibited this decrease with only slightly reduced levels of BCL-2 and BCL-X L observed after 24 h of HDACi (Figure 3d ). Taken together, the data indicate that HDACi results in reduced expression of the prosurvival proteins, BCL-2 and BCL-X L , and that MYC is necessary to mediate the HDACi-induced decrease of BCL-2 and BCL-X L .
HDACi induces apoptosis in breast and lung cancer cells. To test whether the decrease in the expression of prosurvival proteins BCL-2 and BCL-X L results in apoptosis, human breast and lung cancer cell lines were treated with Depsi or vehicle control (DMSO) and several assays were performed. There was an obvious reduction in cell Figure 3) . These data demonstrate that as BCL-2 and BCL-X L levels decrease in breast and lung cancer cells following HDACi, apoptosis occurs.
To determine whether ectopic expression of BCL-2 and/or BCL-X L could protect human carcinoma cells from HDACiinduced cell death, BCL-2 and/or BCL-X L were overexpressed in MDA-MB-231 (breast) and A549 (lung) cancer cells. In the presence of Depsi, both cell lines overexpressing BCL-2 and/ or BCL-X L continued to proliferate at a rate similar to those cells that received DMSO vehicle control (Figure 4e ), demonstrating that they were resistant to Depsi-induced cell death. Collectively, the data show that overexpressing the antiapoptotic proteins BCL-2 and BCL-X L (targets of the miR-15 family and let-7a, respectively) significantly attenuated the induction of HDACi-mediated human breast and lung carcinoma cell death.
miR-15 and let-7 families mediate HDACi-induced apoptosis. Our data suggest that the decrease observed in BCL-2 and BCL-X L protein following HDACi, resulting in apoptosis, was the direct consequence of the upregulation of the miR-15 and let-7 families. To test this directly, we transiently transfected MDA-MB-231 cells with modified RNA molecules termed Target Protectors that are designed to bind specific sites in the BCL-2 or BCL-X L 3′-untranslated region (UTR) and block the binding of the miR-15 and let-7 families, respectively. In addition, these cells were transfected with luciferase reporters harboring the BCL-2 or BCL-X L 3′-UTR that contain the miR-15 and let-7 family binding sites, respectively. Following HDACi with Depsi, there was a significant decrease in luciferase activity in cells that contained either the BCL-2 or the BCL-X L 3′-UTR, indicating that the miR-15 family and let-7a were upregulated and bound their respective sites in the BCL-2 and BCL-X L 3′-UTR, respectively (Figure 5a ). In contrast, in the presence of the BCL-2 or BCL-X L Target Protector, a decrease in luciferase activity after HDACi was not observed (Figure 5a ). These effects were specific for the individual miRNA and the 3′-UTR, as luciferase activity was not decreased following HDACi in cells containing the BCL-2 3′-UTR and the BCL-X L Target Protector or in cells with the BCL-X L 3′-UTR and the BCL-2 Target Protector (Figure 5a ). These data provide direct evidence that the decrease in BCL-2 or BCL-X L expression following HDACi is due to an upregulation of the miR-15 and let-7 families, respectively, that bind and promote their downregulation.
We also assessed levels of BCL-2 and BCL-X L protein in cells with Target Protectors, following HDACi. When both BCL-2 and BCL-X L Target Protectors were present, the levels of BCL-2 and particularly BCL-X L were maintained even after 24 and 48 h of HDACi (Figure 5b) . Individually, the Target Protectors prevented HDACi-induced downregulation of either BCL-2 or BCL-X L (Supplementary Figure 4) . Evaluation of the effects on cell expansion showed a rapid decrease in the MDA-MB-231 cells treated with Depsi that did not contain any Target Protectors, whereas cells that had received the BCL-2 and BCL-X L Target Protectors continued to proliferate with HDACi ( Figure 5c ). MDA-MB-231 cells with Target Protectors also showed a significant reduction (~40%) in the percentage of Annexin-V-positive apoptotic cells following HDACi (Figure 5d ). In addition, there was less caspase-3 cleavage following HDACi in cells with Target Protectors (Figure 5b and Supplementary Figure 4) . Therefore, blocking the miR-15 and let-7 families from binding BCL-2 or BCL-X L in breast cancer cells prevented the downregulation of BCL-2 and BCL-X L and blunted the apoptotic response resulting from HDACi. Collectively, the data reveal a novel miR-15 and let-7 family-mediated mechanism of apoptosis that underlies HDACi-induced breast and lung carcinoma cell death.
Discussion
In addition to acquiring genetic mutations, cancers can also arise from aberrant epigenetic alterations that modify chromatin accessibility, and thus gene expression.
2 Development of small-molecule inhibitors of HDACs, which function to compact DNA, making it inaccessible, had immediate anticancer application because of their potential to reactivate aberrantly silenced tumor suppressors. 3 Although a number of HDAC inhibitors are being evaluated in preclinical cancer models and clinical trials, much remains unknown about the mechanism of cell death they induce and the molecular determinants of cancer cell sensitivity. In our current study, data demonstrate that inhibition of HDACs in human breast and lung carcinoma cells activates a miRNA-mediated mechanism of apoptosis that is induced by MYC. Our results show that, following HDACi, the MYC-regulated miR-15 and let-7 families are transcriptionally upregulated and they target and downregulate the expression of BCL-2 or BCL-X L , triggering tumor cell apoptosis.
Recently, it has been appreciated that, in addition to proteincoding genes, deregulated expression of noncoding RNA, including miRNA, is a hallmark of tumorigenesis.
1 Although miRNA expression profiling has revealed several miRNA to be upregulated in cancers relative to their normal tissue counterparts, the majority of miRNA are downregulated. 10, 11 These alterations in miRNA expression are beginning to be understood and some have proved to be advantageous in tumorigenesis. For example, miRNA families shown to possess tumor-suppressive properties, 15 such as the miR-15 and let-7 families, are commonly downregulated in human cancers, including breast and lung carcinoma. 10, 11, 13, 14 Altered expression and/or recruitment of HDACs have been shown to contribute to dysregulation of specific miRNA (e.g., miR-29, miR-200b, miR-31, miR-125a, miR-125b and miR-205) in human breast and lung cancers. [5] [6] [7] [8] Our data show that treatment with Depsi (class I HDAC inhibitor), SAHA (pan-HDAC inhibitor) or 966 (HDAC3-selective inhibitor) resulted in elevated levels of mature miRNA of the miR-15 and let-7 families. This increase in miRNA expression was selective as not all miRNA assessed were induced by HDACi. Moreover, this effect was not observed in normal, untransformed PBMCs, indicating tumor cell specificity for HDACi. Notably, the HDAC3-selective inhibitor induced miR-15a and let-7a to an equal extent as Depsi and SAHA, suggesting that HDAC3 is involved in mediating the repression of the miR-15 and let-7 families in carcinoma cells. HDAC3 was reported to repress miRNA expression in hematopoietic malignancies. 5 Evaluation of primary miRNA transcript levels for the miR-15 family and let-7a indicated that the increase in mature miRNA following HDACi was a result of increased transcription of these miRNA. These data were supported by the observed enrichment of phosphorylated RNA polymerase II and the H3K9K14ac histone acetylation mark, which are both indicative of open and transcriptionally active chromatin. These results demonstrate that HDACs, and specifically HDAC3, contribute to the downregulation of the miR-15 and let-7 families in breast and lung cancer, which can be reversed by HDACi.
Dysregulation of the oncogenic transcription factor MYC is known to markedly alter the expression of genes to facilitate cellular proliferation and tumorigenesis. 16 To elicit these effects, MYC coordinates the activation and repression of an extensive network of genes, including miRNA. 18 MYC can repress protein-coding genes and miRNA by recruiting HDACs, including HDAC3. 5, 19 Previously, MYC was reported to repress the miR-15 and let-7 families in B-cell lymphoma, as it was enriched at the promoter regions of these miRNA. 12 Our results, in combination with genome-wide MYC ChIP-sequencing data, 17 indicate that MYC was also present at the promoter regions of the miR-15 and let-7 families in human breast and lung cancer cells. Notably, by knocking down MYC, we determined that MYC was necessary for the upregulation of the miR-15 and let-7 families following HDACi. These data provide mechanistic evidence that MYC uses HDACs, and likely HDAC3 specifically, to transcriptionally silence the miR-15 and let-7 families in breast and lung cancer cells, and that HDACi converts MYC from a repressor to a transcriptional activator at these miRNA promoters.
While induction of tumor cell death has been the biological outcome most often reported following HDACi, 3 and we observed this as well, the molecular determinants responsible for the apoptosis remained incompletely resolved. As such, we investigated known mRNA targets of the miR-15 and let-7 families that, when targeted by these miRNA, lead to cell death. 15 The decrease in BCL-2 and BCL-X L protein we observed following HDACi indicated that the miR-15 and let-7 families were derepressed, and thus, transcriptionally upregulated, targeted BCL-2 and BCL-X L mRNA, respectively. This is supported by our data demonstrating that BCL-2 and BCL-X L mRNA is reduced in human breast and lung cancer cell lines following HDACi. Direct evidence that the cell death observed in the tumor cells following HDACi was due to the downregulation of BCL-2 and BCL-X L by the miR-15 and let-7 families, respectively, was obtained by blocking the binding sites of these miRNA families in the 3′-UTR of BCL-2 and BCL-X L . By inhibiting the miR-15 and let-7 families from binding the 3′-UTR of BCL-2 and BCL-X L , respectively, there was a significant decrease in cell death caused by HDACi. Similarly, overexpression of BCL-2 and/or BCL-X L protected breast and lung cancer cells from HDACi-induced cell death. Other groups have also reported that the forced expression of prosurvival BCL-2 family of proteins can protect multiple malignant cell types from the deleterious effects of HDACi. 3 Additionally, when MYC was knocked down, HDACi had very little effect on BCL-2 and BCL-X L protein expression. This suggested that MYC was required to mediate the HDACiinduced increase in the miR-15 and let-7 families that subsequently targeted BCL-2 and BCL-X L . These results reveal a novel MYC-regulated, miRNA-mediated mechanism of apoptosis that is inactivated in carcinomas, but that can be reactivated by HDACi.
We have demonstrated that inhibition of HDACs in human breast and lung carcinoma cells induces a previously unappreciated tumor suppressor mechanism that uses miRNA to decrease the expression of critical prosurvival proteins, triggering tumor cell death. Activation of this miRNAmediated apoptotic mechanism was dependent on MYC, revealing that HDACi redirected MYC towards apoptosis, which is inactivated in transformed cells. Given that MYC is dysregulated in the majority of human cancers, 16 our results reveal a new MYC-mediated mechanism to induce cell death that could have therapeutic potential in breast and lung cancers. Furthermore, our data suggest that upregulation of the miR-15 and let-7 families and downregulation of prosurvival proteins BCL-2 and BCL-X L could offer a predictive measure of clinical response to HDACi.
